dc.contributor |
Universitat de Barcelona |
dc.contributor.author |
Ascher-Svanum, Haya |
dc.contributor.author |
Novick, Diego |
dc.contributor.author |
Haro Abad, Josep Maria |
dc.contributor.author |
Bertsch, Jordan |
dc.contributor.author |
McDonnell, David |
dc.contributor.author |
Detke, Holland |
dc.date |
2015-06-08T11:55:32Z |
dc.date |
2015-06-08T11:55:32Z |
dc.date |
2014-06-20 |
dc.date |
2015-06-08T11:55:32Z |
dc.identifier.citation |
1176-6328 |
dc.identifier.citation |
649059 |
dc.identifier.uri |
http://hdl.handle.net/2445/65757 |
dc.format |
7 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Dove Medical Press |
dc.relation |
Reproducció del document publicat a: http://dx.doi.org/10.2147/NDT.S61409 |
dc.relation |
Neuropsychiatric Disease And Treatment, 2014, vol. 10, p. 1125-1131 |
dc.relation |
http://dx.doi.org/10.2147/NDT.S61409 |
dc.rights |
cc-by-nc (c) Ascher-Svanum, H. et al., 2014 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by-nc/3.0/es |
dc.subject |
Antipsicòtics |
dc.subject |
Esquizofrènia |
dc.subject |
Qualitat de vida |
dc.subject |
Antipsychotic drugs |
dc.subject |
Schizophrenia |
dc.subject |
Quality of life |
dc.title |
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine. |